Immatics Presents Clinical Activity of IMA402 and IMA203CD8 at ESMO 2026

At the 2026 ESMO Annual Meeting, Immatics reported that its IMA402 bispecific therapy achieved a confirmed objective response rate of 32%, with a median duration of response of 12.5 months and a 1-year overall survival rate of 91% in advanced melanoma patients. The company also completed Phase 1a dose escalation for its IMA203CD8 PRAME cell therapy and is currently enrolling patients with uterine cancer. Furthermore, Immatics plans to start a Phase 1/2 trial for IMA203CD8 in PRAME-positive pediatric cancers in the first half of 2027.